GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q2 FY20 results · Jul–Sep 2019
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹882.02 crore and net profit of ₹502.75 crore for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 882.02 | — | — | 787.97 | +11.9% |
| Other income | 15.88 | — | — | 30.81 | −48.5% |
| Total income | 897.90 | — | — | 818.78 | +9.7% |
| Profit before tax | 587.41 | — | — | 176.11 | +233.5% |
| Net profit for the period | 502.75 | — | — | 113.54 | +342.8% |
| EPS, basic (₹) | 29.68 | — | — | 6.70 | +343.0% |
| Net margin (%) | 57.0 | — | 14.4 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 882.10 | 816.31 | +8.1% | 788.02 | +11.9% |
| Other income | 15.61 | 14.82 | +5.3% | 30.54 | −48.9% |
| Total income | 897.71 | 831.13 | +8.0% | 818.56 | +9.7% |
| Profit before tax | 587.37 | 156.46 | +275.4% | 176.03 | +233.7% |
| Net profit for the period | 502.79 | 100.77 | +398.9% | 113.46 | +343.1% |
| EPS, basic (₹) | 29.68 | 5.95 | +398.8% | 6.70 | +343.0% |
| Net margin (%) | 57.0 | 12.3 | 14.4 |
Consolidated
- Filed with BSE
- 23 Oct 2019, 11:50 IST
- Board meeting
- 22 Oct 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 Oct 2019, 11:50 IST
- Board meeting
- 22 Oct 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE